Analysis
China LSHC Industry Survey Results: 2022 State of Industry in China
Deloitte China Life Sciences & Health Care (LSHC) team conducted our 3rd annual “State of industry” survey for the LSHC market in China during 17th January to 17th February 2022, to better understand pharmaceutical & healthcare players' situation in China with their 2021 final outcome and outlook for 2022.
We would like to thank all participants for providing insights covering
a number of areas ranging from business performance, key elements impacting their business, their 2022 outlook as well as what changes will be impacting their business models, the usage of technologies and digitalization of their operations as a whole.
We have selected some few extracts from our report here below. We hope you'll be interested to know more, and you may download the full report here. Of course, our team is available to individual and specific presentations where we can further elaborate on some of the details.
2021 Performance Review
How did your company perform (top line) in previous year?
Insights
- Overall – actual results in 2021 realized much closer to initial plans unsurprisingly given that 2020 plans were done pre-pandemic
- A large majority of the survey participants are WOFE’s for whom the 2021 results were on target or above (84%)
- Nearly one-third of large companies have experienced a financial performance below their plans (similar to last year survey)
Note: [1] Companies with revenue above 5 Bln RMB; [2] SOE: State-owned Enterprise; [3] POE: Private-owned Enterprise; [4] WOFE: Wholly Foreign-owned Enterprise
Your 2021 business performance was mainly impacted by?
Insights
- Similar to our prior year survey, the focus in 2021 remains on the commercial impacts, especially the regulatory related factors. Thus the impact of VBP and product launch are mentioned by a large majority from all
- As pandemic constraints changed in 2021 - hospital visit & access, were less of an issue compared to 2020
- Nearly half of respondents believe that the local partnership is a sufficient way for market penetration
- Localization of supply chain is mentioned interestingly by only a limited of respondents – and least by larger companies
Online/internet business channel plays critical role during the crisis period, does your company consider to increase investment on these new channels?
Insights
- Vast majority of all respondents indicate that investments into ‘online/internet based channels’ will increase going forward
- Consistent with prior year’s survey results – SOEs and POEs, have a less appetite to do so. While foreign invested companies (WOFE’s and JV’s) have substantially increased their focus to > 80% of all respondents (slightly increased from prior year)
- Foreign invested (JV & WOFE’s) and larger companies indicate that they prefer to expand using online/internet channel through dual angles: partnering but also doing some in-house directly – showing that the risk of dependency eventually requires attention
- SOEs and JV say not to have increased investments into online/ internet channels since a year ago
2022 Future Outlook
How do you foresee your 2022 China business outlook?
Insights
- The 2022 outlook is bright as 60% of them forecast to have over 10% revenue growth in 2022
- Impressive that 13/40 respondents (ca. 30%) from foreign invested companies (WOFE’s) expect growth to be above 15% in 2022
- In a very sharp contrast, 25% of SOEs respondents anticipate to have a revenue decline in 2022
In your latest China market strategy, have you consider the following actions:
Insights
- The product portfolio and value proposition are the most important to large cos, SOEs, and WOFEs, while POEs and JV are focusing on developing China specific model (governance model and talent recruitment model respectively)
- The leverage of resources and policies in special zone (GBA & Hainan FTZ) are less important to all companies, where local government may have to invest more efforts to attract more companies to move in the region
- POEs and JV are both actively looking for partnership to achieve a faster market penetration in China
Note: [1] Companies with revenue above 5 Bln RMB; [2] SOE: State-owned Enterprise; [3] POE: Private-owned Enterprise; [4] WOFE: Wholly Foreign-owned Enterprise
2022 China LSHC Industry Outlook Survey
In Summary: China insight and outlook 2022: extracts from full survey report
The influence power of government sectors is still increasing, especially with the medical pricing reform and data protection regulation updates |
|
More and more companies are formulating more and more a China-specific business model and strategy |
|
The pace of innovation growth has been accelerated as a result of the formulation of various partnerships and R&D investment |